Theragenics adds deal with Imagyn

AuntMinnie.com staff writers
Sep 21, 2000

Brachytherapy firm Theragenics continues to expand its distribution channels. Just days after announcing an agreement with Nycomed Amersham, the Buford, GA-based firm has signed on Imagyn Medical Technologies as a distributor. Imagyn is a minimally invasive and general surgery product provider

Irvine, CA-based Imagyn has signed a five-year, nonexclusive distribution agreement for Theragenics’ TheraSeed, a palladium-103 brachytherapy seed for the treatment of prostate cancer and other solid, localized cancerous tumors. Imagyn will be able to distribute TheraSeed in the U.S., Canada, and Puerto Rico.

TheraSeed will serve as a complement to Imagyn’s isoSTAR, an iodine-125 seed provided to the company by International Isotopes, according to Imagyn chairman, president, and CEO Charles Laverty.

By AuntMinnie.com staff writers
September 22, 2000

Related Reading

Nycomed set to distribute TheraSeed, September 20, 2000

Copyright © 2000 AuntMinnie.com

Latest in Clinical News
Mammogram Patient
40% of women in their 40s forgo biennial breast cancer screening
December 20, 2024
Kidneys
Kidneys appear to tolerate Lu-177 treatments
December 19, 2024
Mri Brain Head
AI algorithm 'harmonizes' brain MRI data from different scanners
December 18, 2024
Prostate Imaging
African American men respond more favorably to Ra-223 therapy
December 17, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Petbrainsmall
Molecular Imaging
Neuroscientists map physiology of feelings
Visual Thumb
MRI
In living color: Stanford researchers peer into human visual system with fMRI
Positracesmall
CT
SMV wins FDA clearance for Positrace hybrid PET/CT camera
More in Clinical News
40% of women in their 40s forgo biennial breast cancer screening
By Amerigo Allegretto
About two in every five women in their 40s do not undergo biennial breast cancer screening per USPSTF recommendations.
December 20, 2024
Mammogram Patient
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
AI algorithm 'harmonizes' brain MRI data from different scanners
By Kate Madden Yee
A novel machine-learning algorithm used with MRI can harmonize brain volumetric data of patients undergoing Alzheimer's disease assessment gathered from different scanners.
December 18, 2024
Mri Brain Head
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
PET visualizes acute graft vs. host disease
By Will Morton
F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.
December 16, 2024
F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.
CBD eases scan-related anxiety in breast cancer patients
By Amerigo Allegretto
Ingesting cannabidiol (CBD) before diagnostic CT or PET scans can reduce anxiety in women with advanced breast cancer.
December 16, 2024
Marijuana Edible Drug 400
Measuring fatty tissue on chest CT predicts esophageal cancer outcomes
By Kate Madden Yee
Measuring visceral adipose tissue volume on unenhanced chest CT may be a useful prognostic factor in patients with esophageal cancer.
December 13, 2024
Fat Tissue Adipocytes
Minimally invasive spine surgeries reduce long-term opioid use
By Will Morton
Minimally invasive image-guided procedures to treat osteoporotic vertebral fractures appear to be effective for decreasing long-term use of pain medication.
December 13, 2024
Spine Pain
RFA successful for treating malignant thyroid nodules
By Amerigo Allegretto
Radiofrequency ablation (RFA) can successfully treat malignant thyroid nodules with minimal adverse events.
December 13, 2024
Thyroid 400
Immuno-PET tracer shows promise in patients with liver cancer
By Will Morton
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.
December 12, 2024
PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.
AI model used with one-inhale CT helps diagnose COPD
By Kate Madden Yee
A convolutional neural network used with a one-inhalation lung CT scan protocol can diagnose and stage chronic obstructive pulmonary disease (COPD).
December 12, 2024
Heart Pulmonary Trunk
Clinical decision support boosts PE diagnostic yield on CTPA
By Kate Madden Yee
Point-of-order clinical decision support improves CT pulmonary angiogram (CTPA) yield of pulmonary embolism (PE) diagnosis, researchers report.
December 11, 2024
Am 2022 06 09 21 09 4701 Pulmonary Embolism Illustration V2 400
Page 1 of 3619
Next Page